Valproic Acid Induces Monoamine Oxidase A via Akt/Forkhead Box O1 Activation

Jason Boyang Wu and Jean C. Shih

Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy (J.B.W., J.C.S.), and Department of Cell and Neurobiology, Keck School of Medicine (J.C.S.), University of Southern California, Los Angeles, California

Received April 4, 2011; accepted July 20, 2011

ABSTRACT

Valproic acid (VPA) has been widely used in clinics for the treatment of multiple neuropsychiatric disorders, such as epilepsy and bipolar disorder. One of the mechanisms by which VPA exerts its effect is through regulating the brain levels of serotonin. However, the molecular basis of this VPA action is not fully understood. Here, we report for the first time that VPA activates monoamine oxidase (MAO) A catalytic activity, mRNA level, and promoter activity. MAO A is a key enzyme that degrades a number of monoamine neurotransmitters, including serotonin. Our results show that VPA increased the phosphorylation of both Akt and Forkhead box O1 (FoxO1), whereas pretreatment of cells with 2-(4-morpholinyl)-8-phenyl-1(4H)benzopyran-4-one hydrochloride (LY294002) (a phosphoinositide 3-kinase inhibitor) reduced the VPA activation of MAO A. Overexpression of FoxO1 dramatically repressed both the basal and VPA-induced MAO A catalytic and promoter activities to 30 to 60%. Small interfering RNA knockdown of FoxO1 attenuated the stimulating effect of VPA on MAO A. Moreover, introduction of a constitutively active form of FoxO1 abolished the activation of MAO A by VPA and Akt. These results suggest that FoxO1 is a repressor for MAO A transcription, and its phosphorylation is involved in VPA activation of MAO A. Sequence analysis, electrophoretic mobility shift and chromatin immunoprecipitation assays further showed the presence of a functional FoxO1-binding site in MAO A core promoter. Taken together, these results demonstrate that MAO A is a novel target for VPA via Akt/FoxO1 signaling pathway. This information provides new insights into the pharmacological mechanisms and therapeutic implications of VPA action.

Introduction

Valproic acid (VPA, 2-propylpentanoic acid, divalproex) has been used clinically for decades as a mood stabilizer and anticonvulsant, primarily for the treatment of epilepsy and bipolar disorder. It is also used for treating migraine headaches and seizures. It has been suggested that VPA exerts its anticonvulsant effect by regulating multiple brain neurotransmitter systems, including serotonin [5-hydroxytryptamine (5-HT)] and dopamine (DA) via the modulation of brain levels as well as intraneuronal metabolism of these neurotransmitters (Johannessen, 2000; Rosenberg, 2007). For example, long-term administration of VPA induced the differential changes of 5-HT level in discrete rat brain regions, such as a decrease of 5-HT in hypothalamus (Baf et al., 1994). Microdialysis studies also revealed an elevation in the metabolites of 5-HT and DA in rats with VPA administration (Horton et al., 1977). However, the molecular basis of VPA action on brain neurotransmission still remains unclear.

Monoamine oxidase (MAO) oxidatively deaminates a number of biogenic and dietary amines including monoamine neurotransmitters (Shih et al., 1999). MAO exists in two isoenzymes, MAO A and MAO B, with 70% identity in amino acid sequences (Bach et al., 1988). MAO A preferentially oxidizes 5-HT, norepinephrine (NE), epinephrine, and DA and is irreversibly inhibited by low concentrations of clorgyline. The catalytic process produces hydrogen peroxide (Shih et al., 1999). MAO A dysfunctions associated with abnormal levels of neurotransmitters, such as 5-HT, have been implicated in numerous neuropsychiatric disorders, such as aggression and antisocial behavior (Shih et al., 1999; Bortolato

ABBREVIATIONS: VPA, valproic acid; 5-HT, 5-hydroxytryptamine; AAA, constitutively active; CA, constitutively active; DA, dopamine; FoxO1, Forkhead box O1; HDAC, histone deacetylase; luc, luciferase; MAO, monoamine oxidase; NE, norepinephrine; PI3K, phosphoinositide 3-kinase; WT, wild type; LY294002, 2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride; DMSO, dimethyl sulfoxide; siRNA, small interfering RNA; PCR, polymerase chain reaction; RT-PCR, reverse transcription-polymerase chain reaction; qPCR, quantitative polymerase chain reaction; IP, immunoprecipitate; NS, nonspecific; FVS, fetal valproate syndrome; E18, embryonic day 18.
Valproic Acid Induces MAO A

et al., 2008). MAO A deficiency caused by a spontaneous mutation in MAO A gene results in impulsive aggressive behavior and mild mental retardation in affected males in a Dutch family (Brunner et al., 1993). MAO A knockout mice also consistently show aggressive behavior (Scott et al., 2008). In this study, we report for the first time that VPA significantly induced MAO A gene expression and demonstrate its molecular mechanisms.

Materials and Methods

Cell Line and Reagents. The human neuroblastoma BE(2)/C cell line was purchased from the American Type Culture Collection (Manassas, VA). BE(2)/C cells were grown in a medium containing 1:1 mixture of Eagle’s minimum essential medium with Earle’s balanced salt solution and Ham’s F12 medium supplemented with 10% fetal bovine serum, 1 mM sodium pyruvate, 0.05 mM nonessential amino acids, 100 U/mL penicillin, and 100 μg/mL streptomycin. All culture materials were purchased from Mediatech (Manassas, VA). E18 rat primary cortical neurons were kindly provided by Dr. Shuhua Chen (Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA). Valproic acid sodium salt was purchased from Sigma-Aldrich (St. Louis, MO) and dissolved in ethanol. 2-(4-Morpholino)-8-phenyl-1H-benzo[4,5]imidazolo[1,2-a]pyridine-4-one hydrochloride (LY294002) was purchased from Cell Signaling Technology (Danvers, MA) and dissolved in DMSO. The equivalent volume of respective vehicle control (ethanol 1% and DMSO for VPA and DMSO for LY294002) was added into the cells in the control group for each experiment with drug treatment. Monoclonal anti-phospho-Akt and anti-FLAG antibodies were purchased from Sigma-Aldrich. Rabbit monoclonal anti-phospho-Akt (Ser473), anti-phospho-Akt (Thr308), anti-Akt, and anti-phospho-Forkhead box 1 (FOXO1) antibodies were purchased from Cell Signaling Technology. Polyclonal anti-FOXO1 antibody was purchased from GenScript (Piscataway, NJ). Human FOXO1 siRNA was purchased from Santa Cruz Biotechnology (Santa Cruz, CA).

Plasmids. Human MAO A 2-1, 1.6, 1.3, and 0.24-kb promoter-luciferase (luc, Firefly) reporter constructs were generated as described previously (Chen et al., 2005; Ou et al., 2006). pGL2-Basic vector was purchased from Promega (Madison, WI). A constitutively active (CA) form of Akt expression construct and the parental pIRES empty vector were a gift from Dr. Bangyan Stiles (Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California). FLAG-tagged wild-type (WT) FOXO1 and constitutively active (AAA) FOXO1 with three mutated phosphorylation sites (T24A, S256A, and S319A) expression constructs in pcDNA vector were a gift from Dr. Kun-Liang Guan (Department of Pharmacology, University of California, San Diego, CA) (Tang et al., 1999).

MAO A Catalytic Activity Assay. One hundred micrograms of total protein (~106 cells) were incubated with 1 mM [3H]-HT in the assay buffer (50 mM sodium phosphate buffer, pH 7.4) at 37°C for 20 min, and the reaction was terminated by the addition of 100 μL of ice-cold 6 N HCl. The reaction products were extracted with benzene/ethyl acetate (1:1) and centrifuged at 4°C for 7 min. The organic phase containing the reaction products was extracted, and the radioactivity was determined by liquid scintillation spectroscopy (Wu et al., 2009a).

RNA Isolation and Quantitative Real-Time RT-PCR. Total DNA-free RNA was purified with TRIzol reagent (Invitrogen, Carlsbad, CA) following the manufacturer’s instructions. Two micrograms of total RNA were used for reverse transcription by Moloney murine leukemia virus reverse transcriptase (Promega) following the manufacturer’s instructions. The reverse transcription products were used as the template for quantitative real-time PCR. Quantitation of PCR products was determined by SYBR Green reagent (Maxima SYBR Green qPCR Master Mix 2X; Fermentas, Glen Burnie, MD) using the iCycler optical system (Bio-Rad, Hercules, CA). The primer sets for MAO A were forward 5′-CTGATGACTGTTGTAAGCT-3′ and reverse 5′-AGCAGCTGAGTAAAGCTTC-3′. The primers for glyceraldehyde-3-phosphate dehydrogenase were forward 5′-GACACACCAAATGATCAG-3′ and reverse 5′-AGCGATGGCACAAGCTGCTG-3′. PCR conditions included an initial denaturation step of 3 min at 95°C followed by 40 cycles of PCR consisting of 30 s at 94°C, 30 s at 60°C, and 40 s at 72°C. The qPCR data were analyzed by the 2-ΔΔCT method (Livak and Schmittgen, 2001)

Western Blotting Analysis. Protein concentrations were determined using the BCA Protein Assay Kit (Pierce, Rockford, IL). Twenty to fifty micrograms of total protein from cells lysed in radioimmuno precipitation assay buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS) supplemented with 1× protease inhibitors (Roche Diagnostics, Indianapolis, IN) and 1× phosphatase inhibitors (Cell Signaling Technology, when required) were separated by 8 to 12% SDS-polyacrylamide gel electrophoresis and transferred to the 0.45-μm pore polyvinylidene difluoride membrane. After the transfer, the membrane was blocked at room temperature for 1 h with 2% bovine serum albumin in PBST (10 mM sodium phosphate, pH 7.2, 150 mM NaCl, and 0.05% Tween 20). The membrane was incubated with anti-pAkt (Ser473) (1:2000), anti-pAkt (Thr308) (1:1000), anti-Akt (1:1000), anti-β-actin (1:4000), anti-pFOXO1 (Ser256) (1:1000), anti-FoxO1 (1:1000), or anti-FLAG (1:1000) antibody in 1% bovine serum albumin in PBST at 4°C overnight. After incubating the membrane with horseradish peroxidase-conjugated secondary antibody against appropriate species at room temperature for 1 h, bands were visualized with the enhanced chemiluminescence Western Blotting Substrates (Pierce). The intensity of bands was quantitated (when required) using ImageJ software (http://rsbweb.nih.gov/ij/) (Wu et al., 2009b).

Stable Cell Line Establishment. WT FoxO1, AAA FoxO1, or the parental pcDNA empty vector was transfected into BE(2)/C cells of 10-cm dish separately. All constructs carry the neomycin-resistant gene. After 24 h, G418 (Geneticin, 750 μg/mL; Sigma-Aldrich), the selective agent, was added into cells. Resistant clones were isolated after the treatment for 10 to 14 days and cultured under the G418 selection continuously. Overexpression of FoxO1 was verified by Western blot. Established stable cell lines were routinely maintained under the G418 treatment at lower concentration (200 μg/mL) (Chen et al., 2011).

Transient Transfection and Luciferase Reporter Assay. Transfections were performed with Lipofectamine 2000 (Invitrogen) or BioT (Bioland, Cerritos, CA) in 12-well plates. pRL-TK (expressing Renilla reniformis luciferase; Promega) was cotransfected as an internal control. The parental empty vector, such as pcDNA, was added to maintain an equivalent amount of DNA in each transfection. After 24- to 48-h incubation, cells were harvested and assayed for luciferase activity using the Dual-Luciferase Reporter 1000 Assay System (Promega).

siRNA Interference. siRNA was transfected into BE(2)/C cells with Lipofectamine 2000 (Invitrogen) following the manufacturer’s instructions. A nonsilencing RNA with sense strand as 5′-UUUCUC-CGAAACGUGUCAAGUUU-3′ was used as a control (Salahpour et al., 2007).

Site-Directed Mutagenesis of MAO A 0.24-kb Promoter. Site-directed mutagenesis was used to mutate the putative FoxO1-binding site as identified in the MAO A 0.24-kb promoter. WT MAO A 0.24-kb luc was used as the template. Mutagenesis was carried out using QuikChange XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) following the manufacturer’s instructions. The primers used for mutagenesis was forward 5′-CCCCCCCGGTAT-CAGGGGAGGATCGGCTCC-3′ (mutated nucleotides are underlined). Mutated nucleotides were verified by DNA sequencing.

In Vitro Translation. In vitro translation was conducted with TNT Coupled Reticulocyte Lysate System (Promega) following the manufacturer’s instructions. Both FLAG-tagged WT FoxO1 con-
struct and the parental pcDNA empty vector carry T7 promoter. In vitro translation products were verified by Western blot.

**Electrophoretic Mobility Shift Analysis.** MAO A 0.24-kb promoter-derived oligonucleotide harboring WT FoxO1-binding site (5'-GGCCGGTTATCAAAAGAGGTCCGAG-3', FoxO1-binding site is underlined) was used as a probe and radioactively labeled by Klenow fill-in reaction. $^{32}$P-Labeled probe was purified using Nuclear Removal Kit (QIAGEN, Valencia, CA). For determining DNA-protein binding, 2 µl of in vitro-translated FoxO1 protein was diluted with 5× binding buffer [20% glycerol, 5 mM MgCl$_2$, 2.5 mM EDTA, 2.5 mM dithiothreitol, 50 mM NaCl, 50 mM Tris-HCl, pH 7.5, and 0.25 mg/ml poly(dI-dC)] in a total volume of 20 µl. One hundred-fold excess of nonradioactively labeled probe (competitor) or 5 µg of anti-FLAG antibody was added, and the mixture was incubated at room temperature for 20 min. $^{32}$P-Labeled probe (~600,000 cpm) was then added, and the mixture was incubated at room temperature for another 20 min. Samples were analyzed on 5% nondenaturing polyacrylamide gel in 1× Tris borate/EDTA buffer at 150 V at room temperature for 3 h. Gel was dried and visualized by autoradiography.

**Chromatin Immunoprecipitation Assay and PCR.** BE(2)C cells were transfected with FLAG-tagged WT FoxO1; 24 h after transfection, cells were treated with 1 mM VPA or vehicle control for another 24 h. Confluent BE(2)C cells in a 10-cm dish were treated with formaldehyde at the final concentration of 1% at room temperature with gentle shaking for 10 min to cross-link nuclear protein with genomic DNA. Cross-link was quenched by incubating cells with glycine at the final concentration of 0.125 M at room temperature with gentle shaking for another 5 min. Cells were quickly washed by cold phosphate-buffered saline, pH 7.4, twice, harvested by scraping, and centrifuged at 3000 rpm at 4°C for 5 min. Cell pellets were lysed in 350 µl of SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.0, and 2× protease inhibitors) on ice for 10 min, followed by brief sonication using the Branson 450 Sonifier (Branson Ultrasound, Danbury, CT) to shear genomic DNA into ~300- to 500-bp fragments. One percent of the supernatant was saved as input. Supernatant was diluted (1:10) in dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH 8.0, and 167 mM NaCl), and blocked with 60 µl of sheared salmon sperm DNA/protein G agarose at 4°C for 2 to 4 h. The supernatant was immunoprecipitated (IP) with 5 µg of anti-FLAG antibody at 4°C overnight. IgG was used as a negative control for IP. After incubating 40 µl of salmon sperm DNA/Protein G agarose with IP samples at 4°C for another 2 h, beads were sequentially washed by low-salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.0, and 150 mM NaCl), high-salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.0, and 0.5 M NaCl), LiCl buffer (0.25 M LiCl, 1% NP-40, 1% sodium deoxycholate, 1 mM EDTA, and 10 mM Tris-HCl, pH 8.0), and TE buffer (10 mM Tris-HCl, pH 8.0, and 1 mM EDTA). The DNA-protein complex was eluted by elution buffer (1% SDS and 0.1 M sodium bicarbonate) with gentle rotation at room temperature for 15 min twice, reversed cross-linked by the incubation at 65°C overnight, and purified using QIAquick PCR Purification Kit (QIAGEN). Purified DNA was used as the template for the following qPCR analysis. The primers used to target the MAO A promoter region, which encompasses the FoxO1-binding site, were forward 5’-GGCCGGTTATCAAAAGAGGTCCGAG-3’ and reverse 5’-TCCTGGGTCTGAGCCAGAG-3’.

**Statistical Analysis.** Data were presented as the mean ± S.D. from three independent experiments and analyzed with unpaired t test. A p value less than 0.05 was considered as significant.

## Results

**VPA Activated MAO A Catalytic Activity, mRNA Level, and Promoter Activity.** We studied the effect of VPA on MAO A and its molecular mechanisms in a human neuronal BE(2)C cell line, which expresses MAO A (Chen et al., 2005) and well responds to VPA in terms of the activation of known VPA downstream target genes (Hahn et al., 2008). To determine the effect of VPA on MAO A catalytic activity, BE(2)C cells were treated with VPA at various concentrations (0.5, 1, 2, 5, and 10 mM) for 24 h. The concentrations of VPA used under current experimental conditions were within the range of its pharmacological concentrations (Löschner, 1999). Moreover, MTT cell proliferation assay indicated that the cell viability was not affected by VPA at concentrations of up to 10 mM within a 24-h treatment period (data not shown). As shown in Fig. 1A, VPA significantly activated MAO A catalytic activity in a concentration-dependent manner (up to 305%, EC$_{50}$ 1.87 ± 0.28 mM). BE(2)C cells were also treated with 1 mM VPA for different times (12, 24, 36, 48, and 72 h), and the results showed a time-dependent induction of MAO A activity (Fig. 1B; up to 340%, maximum effect achieved within 48 h). It is noteworthy that the increasing tendency of MAO A activity with time is similar between 24- and 48-h VPA treatment (1 mM) (Supplemental Fig. 1), which suggests that the VPA induction of MAO A within 24 h could be due to a kinetic effect rather than binding effect. Moreover, ethanol, as a corresponding vehicle control for VPA, had no significant effect on MAO A activity within a 72-h treatment period (Fig. 1B). We also determined the stimulating effect of VPA on MAO A catalytic activity in E18 rat primary cortical neurons, and likewise, VPA (0.5 and 1 mM) induced MAO A activity in a concentration-dependent manner by up to 230% in this primary neuronal culture system (Supplemental Fig. 2). Next, we investigated whether this induction is at the MAO A mRNA level. As determined by quantitative real-time RT-PCR, MAO A mRNA increased by 2-fold after 24-h VPA (1 mM) treatment (Fig. 1C). Furthermore, VPA (1 mM, 24-h treatment) activated both MAO A 2- and 0.24-kb promoter activities by 122 and 150%, respectively (Fig. 1D). MAO A 0.24-kb core promoter contains a 240-bp region immediately upstream from the transcription initiation site and exhibits the maximum MAO A promoter activity (Zhu et al., 1992). Taken together, these results demonstrate that VPA activated MAO A catalytic activity, mRNA level, and promoter activity.

**Akt Mediated the Induction of MAO A by VPA.** To determine whether VPA initiates the PI3K/Akt signal in the present study, BE(2)C cells were treated with VPA (1 mM) for various times (3, 6, 12 and 24 h). The results of the Western blot show that the phosphorylation levels of Akt at both Ser473 and Thr308 sites markedly increased with time up to 198% (Fig. 2, A and B).

To investigate whether PI3K/Akt mediates the VPA activation of MAO A, BE(2)C cells were treated with 1 mM VPA in the absence or presence of LY294002 (20 µM), a potent PI3K inhibitor that acts immediately upstream of Akt, for 12 h, and MAO A catalytic activity was subsequently determined. As shown in Fig. 2C, MAO A catalytic activity increased by 61% when cells were treated with VPA alone (column 2 versus column 1), whereas this increase was substantially reduced by 60% in the presence of LY294002 (column 3 versus column 2). The efficacy of inhibition of phospho-Akt level by LY294002 was demonstrated by the significantly reduced phospho-Akt band by Western blot (Fig. 2D). This suggests that PI3K/Akt signal mediates the VPA induction of MAO A. To further demonstrate the role of Akt
in activating MAO A activity, we transiently introduced a CA form of Akt expression construct into BE(2)C cells. Likewise, overexpression of Akt increased MAO A activity by 64% (Fig. 2E). The transfection efficiency of CA Akt construct was confirmed by the presence of both transfected phospho- and total Akt bands by Western blot (Fig. 2F). Taken together, these results demonstrate that PI3K/Akt signal mediates the VPA induction of MAO A.

**FoxO1 Mediated the VPA Induction of MAO A**. As shown in Fig. 1, C and D, VPA increased MAO A mRNA level and promoter activity; these results suggest that the VPA activation of MAO A may be at the transcriptional level. FoxO1, a member of the O subclass of the Forkhead family of transcription factors, is an important downstream target of Akt and regulated via the phosphorylation by Akt in PI3K/Akt signaling pathway. Phosphorylated FoxO1 is translocated into the cytoplasm from the nucleus and subjected to ubiquitination (Gross et al., 2008). We have previously observed that expression of FoxO1 and MAO A activity (Fig. 3F, columns 1, 3, and 5); hence, we speculate that FoxO1 might be a potential contributor to the VPA induction of MAO A. To investigate whether VPA induces the phosphorylation of FoxO1, we treated BE(2)C cells with VPA (1 mM) for various times (3, 6, 12, and 24 h). As shown in Fig. 3, A and B, the phospho-FoxO1 (Ser256) level increased with the time by up to 590% in response to VPA, but the total FoxO1 level was not significantly changed. In addition, we established stable BE(2)C cell lines by transfecting FLAG-tagged WT FoxO1 or AAA FoxO1 with three mutated phosphorylation sites (T24A, S256A, and S319A) into cells followed by G418 selection. AAA FoxO1 is sequestered in the nucleus without degradation (Tang et al., 1999). The parental pcDNA empty vector was stably transfected into the control cells. As shown in Fig. 3C, overexpression of WT and AAA FoxO1 repressed the basal MAO A catalytic activity to 31% (column 3 versus column 1) and 20% (column 5 versus column 1), respectively. The VPA-induced MAO A activity was also reduced to 32% in the cells with WT FoxO1 overexpression (Fig. 3C, column 4 versus column 2), which is further exacerbated in the cells with AAA FoxO1 stably expressed (column 6 versus column 4). The successful integration of WT and AAA FoxO1 into the genome of stable cells was confirmed by Western blot using anti-FLAG antibody (Fig. 3D). Moreover, FoxO1 showed a competitive effect with Akt on the regulation of MAO A, given that overexpression of AAA FoxO1 counteracted the activation of MAO A activity by CA Akt (Fig. 3E, column 3 versus column 2). This suggests higher potency of FoxO1 than Akt for regulating MAO A activity.

To demonstrate the effect of VPA and FoxO1 on the MAO A promoter, MAO A 2-kb promoter luciferase (luc) reporter construct (MAO A 2-kb luc) was cotransfected into WT or AAA FoxO1 expression construct into cells followed by the VPA (1 mM, 24 h) treatment. The result showed that cotransfection of WT and AAA FoxO1 repressed the basal MAO A promoter activity to 66% (Fig. 3F, column 6 versus column 1) and 42% (Fig. 3F, column 5 versus column 1), respectively. Similar to the VPA effect on MAO A activity, AAA FoxO1 was more effective than WT FoxO1 in attenuating the activating effect of VPA on the MAO A promoter (Fig. 3F, column 6 versus column 2, and column 4 versus column 2). These results indicate that FoxO1 mediates the induction of both MAO A catalytic and promoter activities in response to VPA.

**Knockdown of Endogenous FoxO1 Diminished the Activation of MAO A by VPA**. We further studied the role of FoxO1 in mediating the VPA induction of MAO A by siRNA interference technology. Knockdown of FoxO1 elevated both...
ties by the basal MAO A catalytic (Fig. 4A, column 3 versus column 1) and promoter (Fig. 4B, column 3 versus column 1) activities by ~2-fold, which is similar to the extent of the VPA induction of MAO A activity in the control cells transfected with nonspecific (NS) siRNA (Fig. 4, A and B, column 2 versus column 1). Successful knockdown of endogenous FoxO1 was confirmed by Western blot (Fig. 4C). The knockdown of FoxO1 diminished the activation of MAO A catalytic activity in response to VPA.

Identification and Validation of a Functional FoxO1-Binding Site in MAO A 0.24-kb Core Promoter

To investigate whether the regulation of MAO A by FoxO1 is due to a direct binding of FoxO1 to the MAO A promoter and to locate a putative FoxO1-binding site(s) in the MAO A promoter, we did serial deletions of MAO A 2-kb promoter linked with luc reporter gene and cotransfected each of them with WT FoxO1 expression construct into BE(2)C cells. It is noteworthy that MAO A promoter-luc constructs consisting of 2-, 1.6-, 1.3-, or 0.24-kb promoter were repressed by FoxO1 to approximately the same extent (Fig. 5A), suggesting that the FoxO1-binding sites are most likely located in the 0.24-kb core promoter region. Sequence analysis of this 0.24-kb region identified a putative FoxO1-binding site (Fig. 5B, middle), which has only one nucleotide different from the canonical site (Fig. 5B, top) (Pierrou et al., 1994; Jonsson and Peng, 2005). Mutation of selective nucleotides at this site (Fig. 5B, bottom) increased the basal MAO A 0.24-kb promoter activity (Fig. 5C, column 3 versus column 1) but abolished the repressing effect of FoxO1 on the MAO A core promoter (Fig. 5C, column 4 versus column 3; p = 0.46, considered as not significant). Moreover, the extent of the activation of MAO A 0.24-kb promoter by VPA was reduced to ~50% when the FoxO1-binding site was mutated (Fig. 5D). These mutation analyses suggest that this FoxO1-binding site is functional and important for the VPA activation of MAO A.

To determine whether FoxO1 directly interacts with this FoxO1-binding site (~116/-110) in MAO A 0.24-kb promoter, we conducted electrophoretic mobility shift analysis with in vitro-translated FoxO1 protein and radioactively labeled FoxO1-binding oligonucleotide derived from the MAO A core promoter as a probe. In vitro-translated FLAG-tagged WT FoxO1 protein was verified by Western blot using both anti-FLAG and anti-FoxO1 antibodies. The parental pcDNA empty vector was used as the template in the protein syn-
thesis for a control (Fig. 6A). No band was observed from the control in which the mock protein synthesized from pcDNA vector was used in the DNA-protein binding reaction (Fig. 6B, lane 2). In contrast, our results showed one radioactive band on the gel when FoxO1 (with FLAG tag) protein was incubated with the probe (lane 3), indicating the presence of a FoxO1-DNA complex. This band was abolished in the presence of 100-fold excess of unlabeled probe as a competitor, suggesting that it is specific for FoxO1 (lane 4). This band was further supershifted when anti-FLAG antibody was incubated in the DNA-protein binding reaction (lane 5). To confirm a FoxO1 association with the MAO A promoter in vivo, we performed chromatin immunoprecipitation assay with BE(2)C cells transiently transfected with FLAG-tagged WT FoxO1 followed by the VPA treatment (1 mM, 24 h). The anti-FLAG immunoprecipitates were subjected to qPCR amplification with primers specific for the MAO A promoter region, which encompasses the FoxO1-binding site. As demonstrated in Fig. 6C, the ectopically expressed FoxO1 was indeed associated with this region (column 1 versus column 2). Moreover, in response to VPA, lower occupancy by FoxO1 in the MAO A promoter with a decrease of 44% was determined in vivo (Fig. 6C, column 3 versus column 1). Taken together, these results demonstrate the interaction of FoxO1 with the MAO A promoter under both in vitro and in vivo conditions.

Taken together, the molecular mechanisms of VPA activation of MAO A is schematically represented in Fig. 7. FoxO1 acts as a transcriptional repressor of MAO A by directly binding to a functional FoxO1-binding site in the MAO A core promoter. In response to VPA signal, the phosphorylation levels of both Akt and its downstream FoxO1 increase.
Fig. 4. Knockdown of endogenous FoxO1 attenuated the VPA induction of MAO A catalytic and promoter activities. A, BE(2)C cells were transfected with NS or FoxO1 siRNA, 24 h after transfection, cells were treated with 1 mM VPA or vehicle for another 24 h followed by MAO A catalytic activity determination (mean ± S.D., n = 3). MAO A catalytic activity with NS siRNA transfected and with the treatment of vehicle was set as 100%. B, MAO A 2-kb luc was cotransfected with either NS or FoxO1 siRNA into BE(2)C cells, 24 h after transfection, cells were treated with 1 mM VPA or vehicle for another 24 h followed by luciferase activity determination (mean ± S.D., n = 3). Activity of MAO A 2-kb luc with NS siRNA transfected and with the treatment of vehicle was set as 100%. C, the knockdown efficiency of endogenous FoxO1 in A and B was determined by Western blot. β-Actin was used as a loading control. Ethanol was used as a vehicle for VPA. Representative gel is shown.

Fig. 5. Identification of a functional FoxO1-binding site in the MAO A 0.24-kb core promoter. A, serially deleted constructs of MAO A promoter-luc were cotransfected with WT FoxO1 construct into BE(2)C cells, 24 h after transfection, the luciferase activity was determined (mean ± S.D., n = 3). Promoterless pGL2 vector was used as a negative control. The parental pcDNA empty vector was cotransfected in the control group for each promoter construct. Percentage of the repression of MAO A promoter-luc by FoxO1 is indicated. Activity of WT MAO A 0.24-kb luc without cotransfection of FoxO1 was set as 100%. B, sequences of the canonical FoxO1-binding site (top), a potential FoxO1-binding site (middle), and the introduced point mutations (italic) used to inactivate the potential FoxO1-binding site (bottom). C, WT or mutated (Mut, harboring selective nucleotide mutations at the FoxO1-binding site as indicated in B) MAO A 0.24-kb luc was cotransfected with wild-type FoxO1 construct into BE(2)C cells, 24 h after transfection, the luciferase activity was determined (mean ± S.D., n = 3). The parental pcDNA empty vector was cotransfected in the control group for each promoter construct. Activity of WT MAO A 0.24-kb luc without cotransfection of FoxO1 was set as 100%. D, WT or Mut MAO A 0.24-kb luc as used in C was transfected into BE(2)C cells, 24 h after transfection, cells were treated with 1 mM VPA or vehicle for another 24 h followed by luciferase activity determination (mean ± S.D., n = 3). Fold of the activation of WT MAO A 0.24-kb luc by VPA was set as 100%. Ethanol was used as a vehicle for VPA. *, p < 0.05; **, p < 0.01.
phorylated FoxO1 is subjected to nuclear export, which consequently activates MAO A transcription.

Discussion

We demonstrate for the first time that MAO A is a novel target for the anticonvulsant VPA. One of the mechanisms that has been widely accepted for the action of VPA is the increase of the brain levels of the inhibitory neurotransmitter GABA by inhibiting GABA transaminase and thus preventing GABA metabolism. In addition to GABA, it has also been suggested that VPA may exert its anticonvulsant effect through the regulation of monoamine neurotransmitters (Johannessen, 2000; Rosenberg, 2007). For example, the levels of 5-HT, NE, and DA show significant differential changes in discrete regions of the rat brain after long-term administration of VPA (Baf et al., 1994). MAO A is the major enzyme involved in monoamine metabolism (e.g., 5-HT, NE, and DA), and its influences on the behaviors of humans and mice have been well established (Shih et al., 1999; Bortolato et al., 2008). Hence, it is possible that the regulation of MAO A serves as one of the mechanisms by which VPA modulates monoaminergic neurotransmission and exerts its therapeutic effect.

VPA is one of the first-line treatment drugs for many neuropsychiatric disorders, such as bipolar disorder; however, the adverse effect when clinically used in pregnancy has been reported since the 1980s, which results in the fetal valproate syndrome (FVS). This disease is initiated and progressed along the developmental course in the human embryo and fetus and later displays autistic-like behaviors and other physical anomalies in children. Likewise, such VPA effect has been validated in most animal species (Ornoy, 2009). For example, maternal administration of VPA induces behavioral impairments in juvenile rats, which mimic some aspects of autistic phenotypes. Impairments of the serotonergic system, which are often observed in human autism, have been shown in the initiation/progression of FVS and further suggested to be involved in the pathogenesis of FSV. Abnormalities of serotonergic neuronal differentiation and migration in animal models of FVS have been demonstrated both in vitro and in vivo (Miyazaki et al., 2005; Dufour-Rainfray et al., 2010). These studies suggest that VPA could have a direct or indirect action on the embryonic development of the serotonergic system.

The potential mechanisms by which VPA regulates the serotonin level may involve different serotonin regulators in the serotonergic system. Previous studies have revealed that VPA is capable of affecting the activities of tryptophan hydroxylase, the enzyme responsible for serotonin synthesis (Shukla, 1985), and certain subtypes of serotonin receptors such as 5-HT2A (Sullivan et al., 2004) and 5-HT1B receptors (Redrobe and Bourin, 1999). MAO A uses serotonin as a substrate, and MAO A dysfunctions associated with a serotonin imbalance have been implicated in multiple mental disorders including depression, social anxiety, and autism (Shih et al., 1999; Bortolato et al., 2008). It would be interesting to investigate whether the region-specific variation of brain serotonin level as observed in the pathogenesis of FVS could be partially resulted from the misregulation of MAO A.
by VPA. Moreover, current findings may also help us develop better therapeutic strategies for treating the pregnant patients with a required clinical use of VPA, such as a combination treatment with MAO inhibitors.

We show that VPA induces MAO A via the activation of Akt/FoxO1 signaling pathway. VPA has shown the capability to induce selective cellular signaling pathways including PI3K/Akt and extracellular signal-regulated kinase pathways, which eventually activate downstream transcription factors such as c-Jun, c-Fos, and β-catenin via differential regulations of mediators such as glycogen synthase kinase-3β (GSK-3β), to control the transcription of target genes (Kostrouchova et al., 2007). Pretreatment of cells with LY294002, a potent PI3K inhibitor, reduced the VPA induction of MAO A (Fig. 2C), indicating a mediating role of Akt. However, the effective suppression of Akt activity (Fig. 2D) did not abolish this induction completely (Fig. 2C, column 3 versus column 1, \( p < 0.05 \)). This suggests that Akt activation may act as a central signal coupled with other signals/regulators to mediate the VPA induction of MAO A.

Transcription factor FoxO1 plays an important role in many physiological processes. FoxO1 is regulated by several modifications, but one of the most critical is phosphorylation and nuclear exclusion by Akt (Gross et al., 2008). The present study demonstrates for the first time the responsiveness of FoxO1 to VPA and the repressing effect of FoxO1 on MAO A (Fig. 3). VPA-induced phosphorylation of FoxO1 allows the nuclear export of FoxO1 and its subsequent ubiquitination. The shuttle of FoxO1 between the nucleus and cytoplasm is a key determinant for its activity and a master event for the regulation of MAO A by VPA. Introduction of AAA FoxO1, which escapes the degradation, completely abolished the VPA-induced activation of MAO A catalytic and promoter activities (Fig. 3, C and E). FoxO1 repressed MAO A by directly binding to a functional FoxO1 binding-site in the MAO A core promoter. Mutation of this site diminished the repressing effect of FoxO1 on the MAO A promoter (Fig. 5C) but still retained ~50% of the activation of MAO A promoter by VPA (Fig. 5D), which suggests a potential contributing role(s) of other MAO A regulators in this induction. In addition to the activation of the basal MAO A activity, siRNA knockdown of endogenous FoxO1 also attenuated the stimulating effect of VPA on MAO A (Fig. 4, A and B). This is, to some extent, consistent with the reported FoxO1-Akt feedback mechanism. The knockdown of FoxO1 decreases the sensitivity of Akt phosphorylation to extracellular signals (e.g., VPA in the present study) (Matsumoto et al., 2006), which reduces the Akt-mediated phospho-FoxO1 level, retains more FoxO1 in the nucleus, and further counteracts the VPA induction of MAO A.

VPA has demonstrated its role as a histone deacetylase (HDAC) inhibitor (Göttlicher et al., 2001; Phiel et al., 2001). HDACs play an important role in the regulation of gene transcription by chromatin structure remodeling and dynamic changes in nucleosomal packaging of DNA. Inhibition of HDAC increases histone acetylation and maintains chromatin structure in a more open conformation, which leads to the transcriptional activation via the recruitment of activator proteins (Richon and O’Brien, 2002; Marks et al., 2003). Two well known HDAC inhibitors, sodium butyrate and trichostatin A, showed stimulating effect on both MAO A catalytic and promoter activities by ~2-fold in the present cellular environment.
system (Supplemental Fig. 3). This supports the hypothesis that VPA may induce MAO A by modulating the acetylation status of MAO A promoter. Moreover, VPA has shown previously the capability to increase Sp1 acetylation (Marinova et al., 2009), a key transcriptional activator of MAO A by directly binding to the Sp1 sites in the MAO A core promoter (Zhu et al., 1994; Shih et al., 2011). This further suggests the possibility that Sp1 and other potential VPA-responsive MAO A regulators may also contribute to the induction of MAO A by VPA via diverse mechanisms such as histone acetylation.

In summary, we report for the first time that VPA activates MAO A gene expression and demonstrate the molecular mechanisms via the activation of Akt/FoxO1 signaling pathway. This study provides new insights into the molecular mechanisms of VPA action and helps in the understanding of its therapeutic implications in the treatment of multiple neuropsychiatric disorders.

Acknowledgments

We thank Dr. Bangyan Stiles for providing human constitutively active Akt expression construct, Dr. Kun-Liang Guan for providing human wild-type and constitutively active FoxO1 expression constructs, and Dr. Shuhua Chen for providing E18 rat primary cortical neurons.

Authorship Contributions

Participated in research design: Wu and Shih.
Conducted experiments: Wu.

Performed data analysis: Wu and Shih.

Wrote or contributed to the writing of the manuscript: Wu and Shih.

References


Address correspondence to: Dr. Jean C. Shih, Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, 1985 Zonal Avenue, PSC 518, Los Angeles, CA 90089. E-mail: josh@usc.edu